v3.26.1
Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development expenses $ (275)
General and administrative expenses, exclusive of depreciation and amortization (1,899) (503)
Change in fair value of contingent consideration 343
Goodwill impairment (6,291)
Depreciation and amortization (103)
Operating loss (8,225) (503)
Financing expense, net (100) (716)
Other income 386
Changes in fair value of investments measured under the fair value option (Notes 5, 6, 7) 492 103
Net loss before tax (7,447) (1,116)
Income taxes 23
Net loss from continuing operation (7,424) (1,116)
Net gain (loss) from discontinued operations (Note 8) 835 (141)
Net loss (6,589) (1,257)
Less: Net loss attributable to non-controlling interests 9 64
Net loss attributable to the Company’s stockholders’ equity $ (6,580) $ (1,193)
Loss per share from continuing operations (basic) [1] $ (12.10) $ (15.87)
Profit (loss) per share from discontinued operations (basic) [1] 1.36 (2.13)
Total loss per share (basic) $ (10.74) $ (18.00)
Weighted average number of shares of Common Stock outstanding - basic [1] 612,715 66,264
Loss per share from continuing operations (diluted) [1] $ (12.10) $ (83.12)
Profit (loss) per share from discontinued operations (diluted) [1] 1.36 (2.13)
Total loss per share (diluted) $ (10.74) $ (85.25)
Weighted average number of shares of Common Stock outstanding – diluted [1] 612,715 101,975
Comprehensive income (loss):    
Other comprehensive loss - Foreign currency translation adjustments $ 4 $ (6)
Comprehensive income (loss) (6,585) (1,263)
Other comprehensive income (loss) attributable to non-controlling interests 9 66
Comprehensive loss attributable to the Company’s stockholders $ (6,576) $ (1,197)
[1] Adjusted to reflect one (1) for seven (7) reverse stock split in April 2026 (see note 1B).